Ayala Pharmaceuticals Inc (ADXS)

[ignatiusrielly35]

What I’m suggesting is that perhaps Amgen realized NEO is difficult and that HOT is a threat, being cheaper and faster. So if production costs played into that thinking, that would be consistent. What I am also wondering is if ADXS turned up the heat by starting HOT with NSCLC. Possible that all of these factors played a role. I don’t personally buy that such preliminary NEO data as would be available would permit a conclusion regarding efficacy. The only remarkable result would be surprising immediate response. A lack of response would be disregarded.